Affimed N.V.
(NASDAQ:AFMD)
$0.52
0.07 (16.44%)
At Close: 4:00 PM
AFMD Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
AFMD Stock Price Today
Affimed N.V. (AFMD) stock rallied over 16.44% intraday to trade at $0.524 a share on NASDAQ. The stock opened with a loss of -24.89% at $0.34 and touched an intraday high of $0.34, rising 16.44% against the last close of $0.45. The Affimed N.V. in stock market went to a low of $0.22 during the session.
AFMD Stock Snapshot
$0.45
Prev. Close
78.25 Million
Market Cap
$0.22
Day Low
$0.34
Open
N/A
Number of Shares
$0.34
Day High
N/A
P/E ratio
-0.85
EPS (TTM)
0.65
Cash Flow per Share
N/A
Free Float in %
0.51
Book Value
927164.00
Volume
AFMD Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta2.05
Sales or Revenue$21.02 Million
5Y Sales Change238.86%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Peers
Frequently Asked Questions
What is the current Affimed N.V. (AFMD) stock price?
Affimed N.V. (NASDAQ: AFMD) stock price is $0.52 in the last trading session. During the trading session, AFMD stock reached the peak price of $0.34 while $0.22 was the lowest point it dropped to. The percentage change in AFMD stock occurred in the recent session was 16.44% while the dollar amount for the price change in AFMD stock was $0.07.
AFMD's industry and sector of operation?
The NASDAQ listed AFMD is part of Biotechnology industry that operates in the broader Healthcare sector. Affimed N. V.
Who are the executives of AFMD?
Dr. Wolfgang Fischer
MD, Chief Operating Officer & Member of Management Board
Mr. Angus W. Smith
Chief Financial Officer & Member of Management Board
Dr. Adi Hoess M.D., Ph.D.
Chief Executive Officer, MD & Member of Management Board
Mr. Alexander Fudukidis
Head of Investor Relations
How AFMD did perform over past 52-week?
AFMD's closing price is 0.57% higher than its 52-week low of $0.2235 where as its distance from 52-week high of $2.55 is -0.78%.
How many employees does AFMD have?
Number of AFMD employees currently stands at N/A. AFMD operates from Technologiepark, Heidelberg, 69120, DE.
Link for AFMD official website?
Official Website of AFMD is: https://www.affimed.com
How do I contact AFMD?
AFMD could be contacted at phone #49 6221 6743 60 and can also be accessed through its website. AFMD operates from Technologiepark, Heidelberg, 69120, DE.
How many shares of AFMD are traded daily?
AFMD stock volume for the day was 927164.00 shares. The average number of AFMD shares traded daily for last 3 months was 571.45 Thousands.
What is the market cap of AFMD currently?
The market value of AFMD currently stands at $78.25 Million with its latest stock price at $0.52 and N/A of its shares outstanding.